FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: cancer treatment

Sort
E.g., 2013-05-24
E.g., 2013-05-24
Enter a comma separated list of user names.

Cellceutix Corporation has made two significant announcements this week pertaining to Kevetrin, their flagship compound for the treatment of drug-resistant cancers. Not only has pre-clinical data produced very promising data as a therapy for breast, lung and colon cancer, the recent data as clinical trials approach this year can only be considered big news for the cancer industry.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) previously reported that CBLB502, a drug under development to treat exposure to radiation, has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.

Proteonomix, Inc. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with Proteonomix's Joint Venture Company, XGEN Medical LLC ("XGen") towards implementing operations in the United Arab Emirates (U.A.E.).

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Proteonomix, Inc., (OTCBB:PROT.OB) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's successful international approach to commercializing its proprietary and patent pending stem cell technologies.

ADVERTISE WITH US